Stryker, Johnson & Johnson and Zimmer Biomet posted their first-quarter financial results for 2026 and data on their spine orthopedic sales.
Here is how they compare:
Total sales: $6 billion (+2.6%)
Orthopedics: $2.8 billion (+0.1%)
Hips: $460 million (+3.7%)
Knees: $670 million (+4.7%)
MedSurg and Neurotechnology: $3.2 billion (+5%)
Net earnings: $745 million
Key headlines:
- Launched the Ortho Tech business, combining orthopedic instruments and Mako portfolios
- Named to Fortune’s 2026 list of the “100 Best Companies to Work For.”
Total sales: $2.1 billion (+9.3%)
Hips: $524.1 million (+5.7%)
Knees: $828.6 million (+4.5%)
Sports medicine, extremities, trauma, craniomaxillofacial and thoracic: $562 million (+19.5%)
Net earnings: $238.1 million
- Added Chief Science, Technology and Medical Affairs Officer Jonathan Vigdorchik, MD
- Completed $250 million of share repurchases during the first quarter of fiscal 2026
- Debuted the G7TM Acetabular System
Medtech sales: $8.6 billion (+7.7%)
Orthopedic: $2.4 billion (+6.3%)
Spine, sports and other: $833 million (+7.9%)
Hips: $436 million (+6.5%)
Knees: $420 million (7.9%)
Net earnings: $5.2 billion
Key headlines:
- Johnson & Johnson is considering a mutlibillion sale of its orthopedic business.
- New product launches were a major driver for the U.S. orthopedics business.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
